BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Horiuchi H, Sasaki H, Miyazaki K, Miyata N, Yoshimura Y, Tachikawa N. Recovery from severe persistent COVID-19 without evidence of an anti-SARS-CoV-2 antibody response in a man with mantle cell lymphoma treated with rituximab. J Infect Chemother 2021:S1341-321X(21)00329-9. [PMID: 34887178 DOI: 10.1016/j.jiac.2021.11.018] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Shimizu A, Shirai I, Ogawa K, Miura A, Haruhara K, Oshiro K, Hamaguchi A, Yokote S, Okabe M, Ueda H, Tsuboi N, Ikeda M, Yokoo T. Persistent SARS-CoV-2 Infection in a Patient with Nephrotic Syndrome under Rituximab Therapy: Successful Treatment with a Combination of Remdesivir and Monoclonal Antibodies. Intern Med 2022;61:3703-8. [PMID: 36171121 DOI: 10.2169/internalmedicine.0241-22] [Reference Citation Analysis]
2 Dioverti V, Salto-alejandre S, Haidar G. Immunocompromised Patients with Protracted COVID-19: a Review of “Long Persisters”. Curr Transpl Rep 2022. [DOI: 10.1007/s40472-022-00385-y] [Reference Citation Analysis]
3 Maekura C, Muramatsu A, Nagata H, Okamoto H, Onishi A, Kato D, Isa R, Fujino T, Tsukamoto T, Mizutani S, Shimura Y, Kobayashi T, Okumura K, Inaba T, Nukui Y, Kuroda J. Clinical Implication of the Effect of the Production of Neutralizing Antibodies Against SARS-Cov-2 for Chronic Immune Thrombocytopenia Flare-Up Associated with COVID-19 Infection: A Case Report and the Review of Literature. Infect Drug Resist 2022;15:2723-8. [PMID: 35668857 DOI: 10.2147/IDR.S360238] [Reference Citation Analysis]
4 . Multiple drugs. Reactions Weekly 2022;1903:275-275. [DOI: 10.1007/s40278-022-13837-y] [Reference Citation Analysis]